Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
A new AMA policy provide guidance for physician-scientists on dual-use research issues and reinforces the message that ethical conduct in scientific research ultimately rests with the individual researcher.
Physicians are obligated in many jurisdictions to perform life-sustaining treatments on premature infants with serious developmental or physical impairments, even if it goes against the parents' wishes.